Literature DB >> 26772441

Assessment of Valvular Disorders in Survivors of Hodgkin's Lymphoma Treated by Mediastinal Radiotherapy ± Chemotherapy.

Jesse M Bijl1, Marleen M Roos2, Elena M van Leeuwen-Segarceanu3, Josephine M Vos3, Willem-Jan W Bos2, Douwe H Biesma4, Marco C Post5.   

Abstract

As the number of Hodgkin's lymphoma (HL) survivors grows, understanding long-term complications becomes more important. Mediastinal radiotherapy (MRT) seems to cause valvular disease, and the prevalence might increase during follow-up. In this cross-sectional study 82 HL survivors participated (52% men, mean age 47.8 years, 50 treated with MRT). Valvular disease was diagnosed by transthoracic echocardiography and compared between HL survivors treated with and without MRT. Univariate and multivariate logistic regression analysis was used to identify predictors for valvular disease. During a median follow-up of 13.4 years (range 2 to 39 years), ≥ mild valvular disease was present in 61.2% of HL survivors with MRT (n = 30), compared with 31.0% of HL survivors without MRT (n = 9; odds ratio [OR] 3.51, 95% CI 1.32 to 9.30, p = 0.01). In multivariate analysis, only current age remained predictive for ≥ mild valvular disease (OR 1.08 per year, 95% CI 1.01 to 1.14, p = 0.023). Aortic regurgitation (AR) was most prevalent and irradiated patients had significantly more ≥ mild AR (38.2% vs 6.8%, p = 0.007). Within the MRT subgroup, time after radiation of >15 years was associated with AR (OR 4.70, 95% CI 1.05 to 21.03, p = 0.043), after adjusting for current age and hypertension. Severe valvular disease was present in 24.5% of HL survivors with MRT compared with 3.4% without MRT (p = 0.016). Valvular surgery was performed in 9 HL survivors (18.0%) with MRT and in none without MRT. In conclusion, the prevalence of valvular disease in HL survivors treated with MRT is high and increases with time after irradiation. Long-time screening for valvular disease by transthoracic echocardiography might be worthwhile.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26772441     DOI: 10.1016/j.amjcard.2015.11.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  Cardiovascular Risk in Cancer Survivors.

Authors:  Inbar Agmon Nardi; Zaza Iakobishvili
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-28

Review 2.  Radiation-Induced Cardiovascular Disease.

Authors:  Deepa Raghunathan; Misha Iftikhar Khilji; Saamir A Hassan; Syed Wamique Yusuf
Journal:  Curr Atheroscler Rep       Date:  2017-05       Impact factor: 5.113

Review 3.  Cardio-Oncology Education and Training: JACC Council Perspectives.

Authors:  Jose A Alvarez-Cardona; Jordan Ray; Joseph Carver; Vlad Zaha; Richard Cheng; Eric Yang; Joshua D Mitchell; Keith Stockerl-Goldstein; Lavanya Kondapalli; Susan Dent; Anita Arnold; Sherry Ann Brown; Monica Leja; Ana Barac; Daniel J Lenihan; Joerg Herrmann
Journal:  J Am Coll Cardiol       Date:  2020-11-10       Impact factor: 24.094

Review 4.  Pregnancy Among Survivors of Childhood Cancer: Cardiovascular Considerations.

Authors:  Michael C Honigberg; Amy A Sarma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-06-19

Review 5.  Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management.

Authors:  Merrill H Stewart; Eiman Jahangir; Nichole M Polin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

Review 6.  Cardiac Remodelling Following Cancer Therapy: A Review.

Authors:  Tan Panpan; Du Yuchen; Shi Xianyong; Liu Meng; He Ruijuan; Dong Ranran; Zhang Pengyan; Li Mingxi; Xie Rongrong
Journal:  Cardiovasc Toxicol       Date:  2022-07-25       Impact factor: 2.755

Review 7.  Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

Authors:  Peggy M Kostakou; Nikos T Kouris; Vassilios S Kostopoulos; Dimitrios S Damaskos; Christoforos D Olympios
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

8.  High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?

Authors:  Anne Andersson; Gunilla Enblad; Martin Erlanson; Ann-Sofie Johansson; Daniel Molin; Björn Tavelin; Ulf Näslund; Beatrice Melin
Journal:  Ups J Med Sci       Date:  2021-02-15       Impact factor: 2.384

Review 9.  Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience.

Authors:  Michael G Fradley; Allen C Brown; Bernadette Shields; Federico Viganego; Rongras Damrongwatanasuk; Aarti A Patel; Gregory Hartlage; Natalee Roper; Julie Jaunese; Larry Roy; Roohi Ismail-Khan
Journal:  Oncol Rev       Date:  2017-07-18

Review 10.  Cardiotoxicity of mediastinal radiotherapy.

Authors:  Ivica Ratosa; Maja Ivanetic Pantar
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.